SNMMI 2020 virtual conference recognizes leaders in biomarker research and imaging

Image of the Year and Paper of the Year are two of SNMMI’s most prestigious awards, granted to researchers who demonstrate promising advances in nuclear medicine and molecular imaging. The awards, as well as the latest developments in research and technology, were showcased at this year’s reimagined virtual 2020 conference.

Image of the year courtesy of SNMMI and Hoenig et al.

Each year at its annual conference, Society of Nuclear Medicine and Molecular Imaging (SNMMI) reviewers and society leadership select an image of the year that illustrates the most promising advances in nuclear medicine and molecular imaging. This year, the SNMMI Henry N. Wagner Jr., MD, Image of the Year was awarded to a group of German researchers for their image submitted as part of Abstract 20, “Resistance to Tau and Amyloid Pathology Facilitates Super-Aging.”¹ Selected from more than two thousand abstracts submitted to the meeting, the image depicts “super-agers,” which are older individuals with peak cognitive function and a resistance to the accumulation of tau and amyloid proteins, as compared to “normal-agers” and those displaying mild cognitive impairment (MCI). Based on their findings, the group of researchers concluded that the phenomenon of super-aging, or aging without cognitive impairment, appears to be associated with a resistance to tau and amyloid pathology, as is illustrated with the winning image. The images were acquired with positron emission tomography (PET) using Avid Radiopharmaceuticals’ Florbetapir F 18 (¹⁸F-AV-45 or Florbetapir) and Tauvid (Flortaucipir F18) biomarkers developed to help image distinctive characteristics of Alzheimer’s disease in the brain.

Research from The University of Tennessee College of Medicine-Knoxville (UTCOM-Knoxville) and The University of Tennessee Medical Center (Knoxville, USA) in the non-invasive clinical detection of systemic amyloidosis using PET/CT imaging and a novel amyloid-reactive peptide radiotracer was selected for SNMMI’s 2020 Paper of the Year.² The study evaluated safety, dosimetry and efficacy data on the first 20 patients from the ongoing Phase 1, first-in-human trial of iodine-124 labeled p5+14 in patients with systemic amyloidosis: a disease characterized by fibrillar amyloid deposits in organs such as the heart, liver, spleen, and kidneys. Currently, a systemic amyloidosis diagnosis can only be achieved through biopsy, inferences from anatomic imaging, or changes in serum and urine biomarkers. The researchers concluded the new tracer provided excellent visualization of amyloid-laden organs, notably the heart, liver, spleen, and kidney in patients with systemic amyloidosis, and noted it may provide a novel quantitative method for detecting and monitoring amyloid load.

“Receiving the Henry N. Wagner, Jr., MD, Best Paper Award is a great honor for our research team,” says Jonathan S. Wall, PhD, Director of the Amyloidosis and Cancer Theranostics Program, UTCOM-Knoxville. “We have spent many years developing this new imaging agent for detecting systemic amyloidosis. This work has resulted in our ongoing Phase I/II clinical trial in Knoxville, results from which were described in this year’s paper. The fact that this study has been recognized by the SNMMI is a testament to the incredible work of our multidisciplinary research team, and to the patients who have generously given their time to participate.

“At present it is very difficult to rapidly and accurately diagnose systemic amyloidosis due to the diverse presentation of the disease and how rare it is in the population. For many patients, diagnosis can take three years and often requires a visit to one of the few major amyloid centers in the United States. There are also no current FDA-approved agents for imaging systemic amyloidosis, thus there is a critical need. The agent we developed, ¹²⁴I-p5+14, can not only detect amyloid throughout the body but also provide quantitative data on the amyloid load in each organ. This information can be used to provide a definitive diagnosis, or serve to rule out the disease, and provide invaluable information regarding response to therapy when repeat imaging is performed. We anticipate that ¹²⁴I-p5+14 PET/CT imaging will have a major impact on the management of patients with amyloidosis and as a result of earlier diagnosis, will improve patient outcomes.”